Overview

LY353381 in Preventing Breast Cancer in Women With Hyperplasia

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have hyperplasia. PURPOSE: Randomized phase II trial to study the effectiveness of LY353381 in preventing breast cancer in women who have hyperplasia.
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Estrogen Receptor Modulators
Selective Estrogen Receptor Modulators